Welcome to our dedicated page for Kiora Pharma SEC filings (Ticker: KPHMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kiora Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kiora Pharma's regulatory disclosures and financial reporting.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related stock transaction. On March 3, 2026, he disposed of 238 shares of common stock at $2.02 per share as a tax-withholding disposition, a method of paying tax obligations using shares. After this transaction, he directly owned 45,865 common shares.
Kiora Pharmaceuticals Inc. received an amended Schedule 13G from Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon reporting beneficial ownership tied to warrants for up to 464,676 common shares, or 9.9% of the company based on 3,677,935 shares outstanding as of November 5, 2025. These shares are issuable upon exercise of warrants that include a 9.99% beneficial ownership blocker, so as of the December 31, 2025 event date the reporting persons state they could not exercise the warrants. The filers characterize the position as held in the ordinary course of business and state it is not for the purpose of changing or influencing control.
Kiora Pharmaceuticals, Inc. shareholder AIGH Capital Management LLC and related reporting person Orin Hirschman filed an amended Schedule 13G stating beneficial ownership of 192,984 shares of Kiora common stock as of December 31, 2025. This amount, entirely issuable upon exercise of warrants, represents 4.9% of Kiora’s common stock. The filing notes an additional 514,134 warrant shares are excluded because they are not currently exercisable due to beneficial ownership limitations, and confirms the securities are held in the ordinary course of business without the purpose of influencing control.
Kiora Pharmaceuticals (KPRX) received an amended Schedule 13G from Nantahala Capital Management and affiliates reporting beneficial ownership of 9.99% of the common stock as of September 30, 2025. The group reports 363,712 shares beneficially owned, which includes 207,285 shares that may be acquired within sixty days through the exercise of warrants.
The reporting persons disclose 0 shares with sole voting or dispositive power and 363,712 shares with shared voting and dispositive power. The filing is certified as securities held in the ordinary course and not for the purpose of changing or influencing control.
Kiora Pharmaceuticals (KPRX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and an update on clinical development progress. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and will not be incorporated by reference into other filings unless specifically stated. Kiora’s common stock trades on NASDAQ under the symbol KPRX.
Kiora Pharmaceuticals (KPRX) filed its Q3 2025 Form 10‑Q, showing a small quarterly net income of $26,806, driven by lower operating expenses from collaboration credits and a reduction in contingent consideration fair value. For the nine months, the company recorded a net loss of $4,318,633.
Liquidity remained solid with Cash and Cash Equivalents of $5,508,899 and Short‑Term Investments of $13,866,546. Management states these resources are sufficient to fund planned operations into late 2027. Total assets were $29,863,454 and total liabilities were $7,452,712.
Operating expenses in the quarter benefited from Collaboration Credits of $(1,658,248) and a Change in Fair Value of Contingent Consideration of $(1,721,033), offsetting R&D and G&A. The balance sheet includes Deferred Collaboration Revenue of $1,250,000 tied to an option agreement with Senju.
The company highlighted its TOI license executed in 2024 and ongoing ABACUS‑2 activities. Common shares outstanding were 3,433,491 as of September 30, 2025, and 3,677,935 as of November 5, 2025.
Kiora Pharmaceuticals, Inc. filed a shelf registration on Form S-3 to offer up to $100,000,000 of common stock, preferred stock, warrants, debt securities and/or units. The prospectus describes the company as a clinical-stage ophthalmic biotech developing KIO-301 (a photoswitch for late-stage vision loss such as retinitis pigmentosa), KIO-104 (an intravitreal DHODH inhibitor for retinal inflammatory diseases) and KIO-101 (a topical formulation related to KIO-104). Kiora completed a Phase 1b for KIO-301 and entered a strategic license with Théa Open Innovation providing $16 million upfront, potential milestones up to $285 million and tiered royalties up to the low 20% range; ABACUS-2 (Phase 2) enrollment began in 2Q 2025. KIO-104 Phase 1b/2a showed reductions in intraocular inflammation and edema and a Phase 2 trial began enrollment in 2Q 2025. The company reports orphan designations from FDA and EMA for KIO-301, states its common stock trades on Nasdaq under KPRX and discloses cash and short-term investments expected to fund operations into late 2027, while noting it will need additional financing and that its smaller reporting company status allows reduced disclosure.